Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Jan 2014

Hanna Wedad M, Rüschoff Josef, Bilous Michael, Coudry Renata A, Dowsett Mitch, Osamura Robert Y, Penault-Llorca Frédérique, van de Vijver Marc, Viale Giuseppe

Abstract excerpt

Trastuzumab-containing therapy is a standard of care for patients with HER2+ breast cancer. HER2 status is routinely assigned using in situ hybridization to assess HER2 gene amplification, but interpretation of in situ hybridization results may be challenging in tumors with chromosome 17 polysomy or intratumoral genetic heterogeneity. Apparent chromosome 17 polysomy, defined by increased chromosome enumeration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Amplification
Share to Genetic Heterogeneity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Centromere

Share to Chromosomes, Human, Pair 17

Share to Patient Selection

Share to Receptor, ErbB-2

Share to Trastuzumab

Source

Identifiers

PMID: 23807776
DOI: 10.1038/modpathol.2013.103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.PMID 23807776Read ↗

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.Semantic proximity Read ↗

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 TestingSemantic proximity Read ↗

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistrySemantic proximity Read ↗

Effect of High Copy Number of HER2 Associated With Polysomy 17 on HER2 Protein Expression in Invasive Breast CarcinomaSemantic proximity Read ↗

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity.Semantic proximity Read ↗

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily PracticeSemantic proximity Read ↗

Polysomy 17 and HER-2 Amplification: True, True, and UnrelatedSemantic proximity Read ↗

Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancerSemantic proximity Read ↗

The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the BreastSemantic proximity Read ↗

<i>HER2</i> genetic heterogeneity in breast carcinomaSemantic proximity Read ↗

Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options.Semantic proximity Read ↗

Fluorescence In Situ Hybridization (FISH) as Primary Methodology for the Assessment of HER2 Status in Adenocarcinoma of the BreastSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.